A “significant number of patients” could see a cure for multiple myeloma within the next two decades, one expert told ...

Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced that the U.S. Food and Drug Administration (FDA) approved TECVAYLI® (teclistamab-cqyv) plus DARZALEX ...

Natco Pharma launched a cheaper generic version of the cancer drug ‘Pomalyst’ in the U.S. to treat multiple myeloma, making ...

Clinical trial led by UAB researcher supports approval of new, potentially curative treatment for multiple myeloma ...

The approval was supported by data from the ongoing Phase III MajesTEC-3 study.

Relapsed and refractory multiple myeloma can be difficult to manage, especially as patients progress through multiple lines of therapy and treatment options may become more limited. 1 Since the ...

The recent FDA approval of teclistamab (Tecvayli) in combination with daratumumab (Darzelex) represents a significant shift in the treatment of relapsed/refractory multiple myeloma (R/R MM). According ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Johnson & Johnson has received approval from the U.S. Food and Drug Administration (FDA) for TECVAYLI® (teclistamab-cqyv) in ...

Genetic testing should be offered to myeloma patients to identify high-risk cases earlier and enable more targeted and effective treatment, according to experts. A study by The Institute of Cancer ...

In the rapidly shifting landscape of multiple myeloma treatment, the roadmap for a patient diagnosed in 2026 looks vastly different than it did even a decade ago. In a recent interview with CURE, Dr.

Bonnie was exhausted. It was late 2001, and she’d been working a high-pressure job – barely getting any sleep. “I’d wake up tired, I’d go to bed tired,” she says. She didn’t think much of it, but she ...